Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,999 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: carboplatin Clear all

Conditions: Lung Cancer
Interventions: Carboplatin, Nivolumab, pemetrexed, Ipilimumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumor
Interventions: M6620, Gemcitabine, Cisplatin, Etoposide, Carboplatin, Irinotecan; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 24
States / cities: Phoenix, Arizona • San Diego, California • Stanford, California + 21 more

Conditions: Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions: GEN1042, Pembrolizumab, Cisplatin, Carboplatin, 5-FU, Gemcitabine, Nab paclitaxel, Pemetrexed, Paclitaxel; Biological · Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 23
States / cities: Anchorage, Alaska • Los Alamitos, California • San Diego, California + 19 more

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pembrolizumab, Quality-of-Life Assessment; Drug · Other · Biological
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Neoplasms, Breast
Interventions: Pazopanib, Lapatinib, paclitaxel, carboplatin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: New Brunswick, New Jersey • Cleveland, Ohio • Nashville, Tennessee

Conditions: Breast Cancer
Interventions: Carboplatin, Docetaxel, Trastuzumab (or biosimilar), Pertuzumab (or biosimilar); Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 8
States / cities: Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 3 more

Conditions: Prostate Cancer
Interventions: calcitriol, carboplatin; Dietary Supplement · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Intraocular Retinoblastoma
Interventions: liposomal vincristine sulfate, carboplatin, etoposide; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 6 Years
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2020
U.S. locations: 48
States / cities: Birmingham, Alabama • Tucson, Arizona • Arcadia, California + 40 more

Conditions: Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions: Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation; Radiation · Drug · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 5
States / cities: Gainesville, Florida • Chapel Hill, North Carolina • Hendersonville, North Carolina + 2 more

Conditions: Advanced Solid Tumors
Interventions: ASP1002, Bevacizumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Trifluridine-Tipiracil, Pembrolizumab, Pemetrexed, Carboplatin, Ramucirumab, Docetaxel; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 798 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 15
States / cities: New Haven, Connecticut • Plainville, Connecticut • Gainesville, Florida + 11 more

Conditions: Triple Negative Breast Cancer, Blood and Image Guided, Optimization of Neoadjuvant Therapy, Phase 2
Interventions: Paclitaxel + Carboplatin, Pembrolizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Triple Negative Breast Neoplasms
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 39
States / cities: Mobile, Alabama • Chandler, Arizona • Duarte, California + 33 more

Conditions: Neoplasms, Breast
Interventions: Lapatinib, Trastuzumab; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 8,381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 260
States / cities: Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 221 more

Conditions: Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer
Interventions: Cisplatin, Carboplatin, Paclitaxel, Radiation Therapy; Drug · Radiation
Lead sponsor: Women's Cancer Care Associates, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 6
States / cities: Baltimore, Maryland • Traverse City, Michigan • Morristown, New Jersey + 3 more

Conditions: Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma AJCC v7, Stage II Esophageal Adenocarcinoma AJCC v7, Stage IIA Esophageal Adenocarcinoma AJCC v7, Stage IIB Esophageal Adenocarcinoma AJCC v7, Stage IIIA Esophageal Adenocarcinoma AJCC v7, Stage IIIB Esophageal Adenocarcinoma AJCC v7
Interventions: Carboplatin, External Beam Radiation Therapy, Laboratory Biomarker Analysis, Paclitaxel, Taladegib; Drug · Radiation · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions: doxorubicin HCL liposome; bevacizumab; carboplatin; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Horsham, Pennsylvania

Conditions: HPV, Throat Cancer, Oropharyngeal Carcinoma, Oropharyngeal Cancer, Human Papilloma Virus
Interventions: 18 F-FMISO PET/CT, Radiation, Cisplatin, Carboplatin, 5-fluorouracil; Diagnostic Test · Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Brain Tumors, Central Nervous System Tumors
Interventions: carboplatin, lomustine, procarbazine hydrochloride, thioguanine, vincristine sulfate; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 9 Years
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2012
U.S. locations: 179
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 141 more

Conditions: Salivary Gland Carcinoma, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Salivary Gland Neoplasms
Interventions: 9-ING-41, Carboplatin; Drug
Lead sponsor: Actuate Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2030 – 2034
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Small-cell Lung Cancer
Interventions: Carboplatin, Etoposide, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: Brian Henick, MD; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Bilateral Retinoblastoma, Childhood Intraocular Retinoblastoma, Group D Retinoblastoma, Stage I Retinoblastoma, Unilateral Retinoblastoma
Interventions: Biospecimen Collection, Carboplatin, Etoposide, Examination Under Anesthesia, Magnetic Resonance Imaging, Melphalan, Ultrasound Biomicroscopy, Vincristine; Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 18 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 13 more

Conditions: Carcinoma
Interventions: Paclitaxel, Carboplatin, Bevacizumab, Erlotinib, Treatment determined by physician; Drug · Other
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 21
States / cities: Huntsville, Alabama • Fort Myers, Florida • Jacksonville, Florida + 18 more

Conditions: Lung Cancer, Carcinoma, Non-Small-Cell Lung
Interventions: Docetaxel, Carboplatin, Radiation therapy, Surgical resection; Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Urothelial Carcinoma
Interventions: Erdafitinib, Cetrelimab, Cisplatin, Carboplatin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 12
States / cities: Aurora, Colorado • Louisville, Kentucky • Rockville, Maryland + 9 more

Search by objective public record fields.

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

M6620 First in Human Study

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma

De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study

A Study of ASP1002 in Adults for Treatment of Solid Tumors

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer

A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

Combination Chemotherapy in Treating Children With Progressive Brain Tumors

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Liver Directed RT + Chemo-immunotherapy for ES-SCLC

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer